MAKE A DONATION
Every event, every penny, and every pound helps towards making a difference to the lives of patients living with NMO.
NMO Charitable Funds
Walton Centre: 4911
John Radcliffe: 2131
Request for Rituximab Funding
Rituximab can be beneficial in NMOSD. Its use is generally as a second line agent in preventing relapses.
If the patient has a definite diagnosis of NMOSD, and they have failed first line treatment of an immunosuppressant such as azathioprine, mycophenolate or methotrexate ie they had a further relapse whilst on treatment.
If you think your patient needs Rituximab, please contact the NMOSD service, Walton Centre with the completed form.
NHS Specialised Commissioning Team through NMOSD service have provided additional funding for 12 patients. The patient may be eligible for one year funding of rituximab.
Beyond this the treating Trusts need to obtain reimbursement from the local commissioning hub of NHS England (not from the Walton Centre).